Intracranial atherosclerosis (ICAS) is a major cause of stroke worldwide. Although
approximately 12% of White patients with a history of acute ischemic stroke or transient …

Background and Objective To investigate the efficacy and safety of IV infusion of tirofiban
before endovascular thrombectomy for patients with large vessel occlusion due to …

Importance Tirofiban is a highly selective nonpeptide antagonist of glycoprotein IIb/IIIa
receptor, which reversibly inhibits platelet aggregation. It remains uncertain whether …

The current study by Kellert et al1 stirs up the debate on the potential of glycoprotein IIb/IIIa
antagonists in the therapy of ischemic stroke, and at first sight seems disappointing …

Large vessel occlusion (LVO) strokes are mostly caused by cardioembolism, intracranial
(ICAD) or extracranial atherosclerotic disease (ECAD). Although large artery atherosclerotic …

Background: In the RESCUE BT (Endovascular Treatment With versus Without Tirofiban for
Stroke Patients with Large Vessel Occlusion) trial, enrollment in extended time window was …

In ischemic stroke without large or medium vessel occlusion, tirofiban increased likelihood of
an excellent outcome | Annals of Internal Medicine Advertisement ACP Online Annals of …

Background: Tirofiban, a glycoprotein IIb/IIIa receptor inhibitor, has been shown to reduce
the risk of thrombotic complications during percutaneous coronary intervention. However, it …

We fully agree with the highlighted limitations, which were already mentioned in our article
(eg, higher rate of stenting in the tirofiban group). Of course, the main limitation is the …

Background and Purpose—Chinese patients largely experience acute ischemic stroke (AIS)
because of large artery atherosclerosis rather than cardioembolism, and whether tirofiban is …